Quintanal-Villalonga, Alvaro
Taniguchi, Hirokazu
Zhan, Yingqian A.
Hasan, Maysun M.
Chavan, Shweta S.
Meng, Fanli
Uddin, Fathema
Allaj, Viola
Manoj, Parvathy
Shah, Nisargbhai S.
Chan, Joseph M.
Ciampricotti, Metamia
Chow, Andrew
Offin, Michael
Ray-Kirton, Jordana
Egger, Jacklynn D.
Bhanot, Umesh K.
Linkov, Irina
Asher, Marina
Roehrl, Michael H.
Ventura, Katia
Qiu, Juan
de Stanchina, Elisa
Chang, Jason C.
Rekhtman, Natasha
Houck-Loomis, Brian
Koche, Richard P.
Yu, Helena A.
Sen, Triparna
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Funding for this research was provided by:
National Cancer Institute (R01 CA197936, U24 CA213274, K08 CA-248723, R35 CA263816)
Article History
Received: 16 August 2021
Accepted: 4 October 2021
First Online: 16 October 2021
Declarations
:
: All study subjects had provided signed informed consent for biospecimen analyses under an institutional review board-approved protocol. All animal experiments were approved by the Memorial Sloan Kettering Cancer Center (MSKCC) Animal Care and Use Committee.
: Not applicable.
: AQV reports honoraria from AstraZeneca. MO reports advisory roles for PharMar, Novartis and Targeted Oncology and reports honoraria from Bristol-Myers Squibb and Merck Sharp & Dohme. CMR has consulted regarding oncology drug development with AbbVie, Amgen, Ascentage, Astra Zeneca, Bicycle, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Jazz, Lilly, Pfizer, PharmaMar, Syros, and Vavotek. CMR serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics. AQV and CMR are included on a US patent application entitled, “Methods for predicting and treating chemoresistance in small cell lung cancer patients.”